
Proposed Framework for Counseling Patients about Working during the Pandemic



- A: Instruct the patient to wear a mask outside the home, practice recommended hand hygiene, and use PPE as directed.
- B: Discuss individual risks and opportunities to mitigate exposure and to consider stopping work. Counsel patient to take all precautions outlined in A.
- C: Counsel patient on high risk of continuing to work and to consider stopping work. Counsel patient to take all precautions outlined in A.

Covid-19 in Immune-Mediated Inflammatory Diseases — Case Series from New York

Characteristic	All Patients (N = 86)	Ambulatory Patients (N = 72)	Hospitalized Patients (N = 14)
Mean age (range) — yr	46 (22–74)	46 (22–74)	50 (25–73)
Female sex — no. (%)	49 (57)	42 (58)	7 (50)
Diagnosis of Covid-19 — no. (%)			
Positive	59 (69)	45 (62)	14 (100)
Suspected	27 (31)	27 (38)	0
Primary IMID diagnosis — no. (%)†			
Psoriasis	14 (16)	13 (18)	1 (7)
Psoriatic arthritis	21 (24)	18 (25)	3 (21)
Rheumatoid arthritis	20 (23)	14 (19)	6 (43)
Ulcerative colitis	17 (20)	14 (19)	3 (21)
Crohn's disease	20 (23)	19 (26)	1 (7)
Ankylosing spondylitis	9 (10)	9 (12)	0
BMI‡	27.4±6	26.7±5	30.8±8

Characteristic	All Patients (N = 86)	Ambulatory Patients (N = 72)	Hospitalized Patients (N = 14)
BMI‡	27.4±6	26.7±5	30.8±8
Coexisting conditions — no. (%)			
History of organ transplantation	1 (1)	1 (1)	0
Congestive heart failure	1 (1)	1 (1)	0
Hypertension	11 (13)	6 (8)	5 (36)
Diabetes	5 (6)	3 (4)	2 (14)
Chronic obstructive pulmonary disease	4 (5)	3 (4)	1 (7)
Asthma	15 (17)	15 (21)	0
Currently pregnant	2 (2)	1 (1)	1 (7)

Characteristic	All Patients	Ambulatory Patients	Hospitalized Patients
	(N=86)	(N=72)	(N=14)
Long-term medications — no. (%)			
ACE inhibitor or ARB	13 (15)	8 (11)	5 (36)
Any medication for primary IMID diagnosis	75 (87)	62 (86)	13 (93)
Methotrexate	17 (20)	11 (15)	6 (43)
Hydroxychloroquine	8 (9)	5 (7)	3 (21)
Oral glucocorticoids	8 (9)	4 (6)	4 (29)
Any biologic or JAK inhibitor	62 (72)	55 (76)	7 (50)
Tumor necrosis factor inhibitor	38 (44)	35 (49)	3 (21)
Interleukin-17 blocker	6 (7)	5 (7)	1 (7)
Interleukin-23 blocker	3 (3)	3 (4)	0
Interleukin-12/23 blocker	6 (7)	6 (8)	0
JAK inhibitor	6 (7)	5 (7)	1 (7)

Characteristic	All Patients (N = 86)	Ambulatory Patients (N = 72)	Hospitalized Patients (N = 14)
Hospitalization			
Days from first symptom to hospitalization			5.8±4
Regular floor — no. (%)			12 (86)
Use of supplementary oxygen — no. (%)			7 (50)
ICU-level care, mechanical ventilation, or both — no. (%)			1 (7)
Death — no. (%)			1 (7)

Covid-19 and Kidney Transplantation

At Montefiore Medical Center, we identified 36 consecutive adult kidney-transplant recipients who tested positive for Covid-19 between March 16 and April 1, 2020.

72% were male, median age was 60 years, 39% were black, 42% were Hispanic.

94% had hypertension, 69% had diabetes mellitus, 36% had a history of smoking tobacco or were current smokers, 17% had heart disease.

97% were receiving tacrolimus, 94% were receiving prednisone, and 86% were receiving mycophenolate mofetil or mycophenolic acid.

Outcomes at a median of 21 days (range, 14-28) — no./total no. (%)

Death	10/36 (28)
Intubation	11/28 (39)
Death after intubation	7/11 (64)
Renal replacement therapy	6/28 (21)
Remained hospitalized	12/28 (43)
Discharged from hospital	10/28 (36)